In vitro antifungal susceptibility patterns of planktonic and sessile Candida kefyr clinical isolates

被引:13
|
作者
Nagy, Fruzsina [1 ]
Bozo, Aliz [1 ]
Toth, Zoltan [1 ]
Daroczi, Lajos [2 ]
Majoros, Laszlo [1 ]
Kovacs, Renato [1 ,3 ]
机构
[1] Univ Debrecen, Fac Med, Dept Med Microbiol, Nagyerdei Krt 98, H-4032 Debrecen, Hungary
[2] Univ Debrecen, Fac Sci & Technol, Dept Solid State Phys, Debrecen, Hungary
[3] Univ Debrecen, Fac Pharm, Debrecen, Hungary
关键词
biofilm; echinocandins; caspofungin; amphotericin B; scanning electron microscopy; INTENSIVE-CARE-UNIT; AMPHOTERICIN-B; HEMATOLOGIC MALIGNANCIES; BIOFILMS; CASPOFUNGIN; MICAFUNGIN; VITRO; FLUCONAZOLE; ALBICANS; KEFYR;
D O I
10.1093/mmy/myx062
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The activity of fluconazole, amphotericin B, caspofungin and micafungin was determined using XTT-based fungal damage assays against planktonic cells, early and mature biofilms of Candida kefyr. Median MICs of planktonic cells were 0.25 mg/l, 0.25 mg/l, 0.5 mg/l, and 0.06 mg/l for fluconazole, amphotericin B, caspofungin, and micafungin, respectively. Fluconazole showed at least 50% fungal damage at >= 4 mg/l (51.5% +/- 6.63% to 78.38% +/- 1.44%) and at >= 128 mg/l (57.88% +/- 9.2% to 67.25% +/- 9.59%), while amphotericin B produced an even higher anti-biofilm effect at >= 0.5 mg/l (64.63% +/- 6.79% to 79.5% +/- 5.9%) and at >= 0.12 mg/l (77.63% +/- 8.43% to 92.75% +/- 1.89%) against early and mature biofilms, respectively. In case of micafungin, 50% fungal damage was observed at >= 0.06 mg/l (66.88% +/- 10.16% to 98.63% +/- 1.24%) and >= 0.25 mg/l (74.13% +/- 10.77% to 99.38% +/- 0.38%) for early and mature biofilms, respectively. Caspofungin-exposed cells showed an unexpected susceptibility pattern, that is, planktonic cells showed significantly decreased susceptibility at concentrations ranging from 0.015 mg/l to 1 mg/l compared to biofilms (P < .05-.01). The damage in planktonic cells and biofilms was comparable at higher concentrations. For planktonic cells and biofilms, 50% fungal damage was observed first at 0.5 mg/l (59.75% +/- 3.16%) and at 0.06 mg/l (70.25% +/- 10.95%), respectively. This unexpected pattern was confirmed using scanning electron microscopy. The unusual susceptibility pattern observed at lower caspofungin concentrations may explain the poorer outcome of caspofungin-treated C. kefyr infections documented in certain patient populations. As this phenomenon was markedly less apparent in case of micafungin, these data suggest that micafungin may be a more reliable option than caspofungin for the treatment of C. kefyr infections.
引用
收藏
页码:493 / 500
页数:8
相关论文
共 50 条
  • [41] In vitro antifungal susceptibility testing of Candida isolates from women with recurrent vulvovaginal candidiasis
    Antonopoulou, Stavroula
    Karageorgopoulos, Drosos
    Meletiadis, Joseph
    De Bernardis, Flavia
    [J]. MEDICAL MYCOLOGY, 2018, 56 : S36 - S36
  • [42] Antifungal Susceptibility Testing of Candida Isolates from the Candida Surveillance Study
    Lyon, G. Marshall
    Karatela, Sulaiman
    Sunay, Susan
    Adiri, Yaffa
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (04) : 1270 - 1275
  • [43] Antifungal susceptibility and enzymatic activity of Candida bloodstream isolates
    Ferreira-Paim, K.
    Fonseca, F. M.
    Ferreira, T. B.
    Silva, B. V.
    Silva, L. B.
    Santos, K. C.
    Silva, P. R.
    Andrade, A. A.
    Silva-Vergara, M. L.
    [J]. MYCOSES, 2012, 55 : 242 - 243
  • [44] In Vitro Antifungal Susceptibility of Neoscytalidium dimidiatum Clinical Isolates from Malaysia
    Jasper Elvin James
    Jacinta Santhanam
    Mei Chen Lee
    Choon Xian Wong
    Parameswari Sabaratnam
    Hamidah Yusoff
    Mohd Nizam Tzar
    Mohd Fuat Abdul Razak
    [J]. Mycopathologia, 2017, 182 : 305 - 313
  • [45] In Vitro Antifungal Susceptibility of Neoscytalidium dimidiatum Clinical Isolates from Malaysia
    James, Jasper Elvin
    Santhanam, Jacinta
    Lee, Mei Chen
    Wong, Choon Xian
    Sabaratnam, Parameswari
    Yusoff, Hamidah
    Tzar, Mohd Nizam
    Razak, Mohd Fuat Abdul
    [J]. MYCOPATHOLOGIA, 2017, 182 (3-4) : 305 - 313
  • [46] In vitro Antifungal Susceptibility Testing of Clinical and Environmental Fusarium Isolates in Iran
    Aghaei, Hamed
    Kordbacheh, Parivash
    Kachuei, Reza
    Mahmoudi, Shahram
    Afshari, Setareh Agha Kuchak
    Safara, Mahin
    Zaini, Farideh
    [J]. ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2018, 13 (02):
  • [47] In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis
    Pinto, Patricia M.
    Botelho Weikert-Oliveira, Rita de Cassia
    Lyon, Juliana Pereira
    Cury, Veronica F.
    Arantes, Rodrigo R.
    Koga-Ito, Cristiane Y.
    Resende, Maria A.
    [J]. MICROBIOLOGICAL RESEARCH, 2008, 163 (05) : 579 - 585
  • [48] Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp.
    MartinMazuelos, E
    Aller, AI
    Morilla, D
    Montero, O
    [J]. CHEMOTHERAPY, 1996, 42 (02) : 112 - 117
  • [49] In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida
    Qiao, Jianjun
    Gao, Peiping
    Jiang, Xiaoling
    Fang, Hong
    [J]. ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2013, 12
  • [50] IN VITRO ANTIFUNGAL ACTIVITY OF CRYPTOLEPIS SANGUINOLENTA ON CLINICAL CANDIDA ISOLATES FROM GHANA
    Adjapong, Gloria
    Appenteng, Mark A.
    Kaminta, Sylvester
    Aseidu-Larbi, Jerry
    Ocloo, Augustine A.
    Quarsie, Olga
    Kumadoh, Doris
    Garrill, Ashley
    Mills-Robertson, Felix C.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 554 - 554